

# CUMULATIVE INDEX 2001

## Volume 21

---

March	DIABETES MELLITUS, pages 1-215
June	POINT-OF-CARE TESTING, pages 217-409
September	LABORATORY ASPECTS OF BIOWARFARE, pages 411-696
December	NEW APPLICATIONS OF FLOW CYTOMETRY, pages 697-932

---

Note: Page numbers of article titles are in **boldface** type

- ABI PRISM 7700 Sequence Detection System, for polymerase chain reaction, 640
- Abnormal localization of immature precursors, in myelodysplastic syndrome, 818
- ACE gene, polymorphism of, in diabetic nephropathy, 133
- Acetoacetate, measurement of, in uncontrolled diabetes mellitus, 103-104
- Acetone, measurement of, in uncontrolled diabetes mellitus, 103-104
- Acid-base balance, evaluation of, in uncontrolled diabetes mellitus, 104-105
- Acidosis, diabetic. *See* Diabetes mellitus, uncontrolled.
- Acquired immunodeficiency syndrome. *See* Human immunodeficiency virus infection.
- Activated clotting time (ACT), point-of-care testing for, 346-348
- Activated partial thromboplastin time, point-of-care testing for, 345-346
- Acute care testing, **321-335**  
 accuracy of, 326-328  
 cost issues in, 322-326  
 description of, 321  
 documentation for, 328-330  
 implementation of, 333-334  
 options for, 321-322  
 quality assurance in, 330-333  
 reliability of, 326-328
- Adrenocorticotrophic hormone, measurement of, in hypoglycemia, 92
- Advanced glycation end products, 56-58, 70-71
- AGEs (advanced glycation end products), 56-58, 70-71
- Agroterrorism, **549-591**  
 agents for, 550-552  
 avian influenza, 562-571  
 foot-and-mouth disease, 553-562  
 historical incidents of, 550-551  
 Newcastle disease, 579-585  
 swine fever, 571-578  
 versus natural outbreak, 553  
 vulnerability to, 550
- AIDS. *See* Human immunodeficiency virus infection.
- Albuminuria, in diabetes mellitus, 113-114  
 assays for, 135-137  
 treatment of, 137-138
- Alcohol  
 hypoglycemia due to, 82, 89  
 point-of-care testing for, 369-370
- Aldose reductase, abnormalities of, in diabetic nephropathy, 130, 133
- Alkalosis, in uncontrolled diabetes mellitus, 105
- American Diabetes Association, diabetes classification of, 1-13
- Aminoguanidine, in glycated protein control, 70
- Amniotic fluid, microscopic detection of, 378-379
- Amplification methods, for biowarfare agent detection, 635-636, 640-642, 670-673
- Analytical performance, of point-of-care testing, 223-228

- Anemia, hemolytic, autoimmune, red cell flow cytometry in, 834
- Anergy, in cancer, flow cytometry in, 706-708
- Angiotensin-converting enzyme inhibitors, in diabetic nephropathy, 137-139
- Animals, biowarfare directed to. *See* Agroterrorism.
- Anion gap, measurement of, in uncontrolled diabetes mellitus, 104-105
- Anthrax, in biowarfare, 437-438, 442, 514-523, 664  
detection methods for, 643-644, 668-669, 672  
pathology of, 518-523
- Antibiotic susceptibility testing, of microorganisms, flow cytometry in, 904-907
- Antibody(ies)  
arboviral, tests for, 505-506  
hemoglobin F, in fetomaternal hemorrhage detection, 831  
insulin, measurement of, in hypoglycemia, 92  
insulin receptor, measurement of, in hypoglycemia, 92  
islet cell, in diabetes mellitus, 20-22  
red cell antigen, fetomaternal hemorrhage and, 830-831
- Anticoagulant therapy, point-of-care testing in. *See also* Coagulation testing, point-of-care.  
medical outcome impact of, 293-294
- Antigen(s)  
arboviral, tests for, 504-505  
new, expression of, flow cytometry in, 786-788
- Apoptosis  
assays of, in HIV infection, 850  
excessive, in myelodysplastic syndrome, 813-816  
flow cytometry in, 867-871
- Arachidonic acid metabolites, in biowarfare, 610
- Arbovirus infections, in biowarfare, 495-512. *See also* specific pathogens and diseases.
- Argentine hemorrhagic fever, in biowarfare, 440, 452-455, 478-479
- Arginine, in hyperglycemic clamp test, 44
- Arthropod-transmitted infections, in biowarfare, 495-512. *See also* specific pathogens and diseases.  
clinical features of, 496-497  
diagnosis of  
alertness for, 502-503  
antigen detection in, 504-505  
isolation methods in, 503-504  
laboratory in, 502-508  
reference laboratory role in, 506  
serologic, 505-506  
specimen handling for, 503, 506-508  
surveillance for, 508-509  
distribution of, 496-497  
taxonomy of, 498-502  
unexpected, 502  
vectors for, 496-497
- Atherosclerosis, in diabetes mellitus, 121.  
*See also* Lipid(s), profile of, in diabetes mellitus.  
glycated proteins in, 66
- Atopy, flow cytometry in, 703-706
- Autoimmune disorders  
diabetes mellitus. *See* Diabetes mellitus, type 1.  
hemolytic anemia, red cell flow cytometry in, 834
- Automated Coagulation Timer device, 340
- Avian influenza, in biowarfare, 562-571  
clinical features of, 564  
definition of, 562  
diagnosis of, 569-571  
etiology of, 562  
geographic distribution of, 563  
hosts for, 562-563  
incubation period for, 564  
morbidity and mortality in, 569  
pathology of, 565-569  
public health implications of, 571  
transmission of, 563-564
- AvoSure devices, 340
- B-cell amplifier, for biowarfare agent detection, 687
- B lymphocytes  
in beta cell destruction, 25  
leukemia of, flow cytometry in, 805  
lymphomas of, flow cytometry in, 764-766, 769-772
- Babesiosis, red cell flow cytometry in, 835-836
- Bacillus anthracis* infections, in biowarfare, 437-438, 442, 514-523, 664  
detection methods for, 643-644, 668-669, 672
- Bacillus subtilis* infections, in biowarfare, 623
- Barophiles, in biowarfare, 623
- Bax gene transfer, to mitochondria, flow cytometry in, 870
- Beads, microscopic, in flow cytometry. *See* Suspension array technology.
- Bedside testing. *See* Point-of-care testing.
- Beta cells  
antibodies to, in diabetes mellitus, 20-22  
decrease of, insulin resistance in, 35  
destruction of, diabetes mellitus in, 2, 15-16, 22-23

- dysfunction of  
 causes of, 34-36  
 clinical features of, 36-38  
 in cirrhosis, 200-201  
 laboratory assessment of, 42-45  
 function of, versus insulin sensitivity, 45  
 genetic defects of, diabetes mellitus in, 3-4  
 iron deposition in, 199
- Bicarbonate, administration of, in  
 uncontrolled diabetes mellitus, 107
- Bile acid sequestrants, in  
 hypertriglyceridemia, in diabetes  
 mellitus, 167
- Bilirubinuria, point-of-care testing for, 391
- Billing, for point-of-care testing, 329-330
- Biomunitions, development of, 428-430
- Bioregulators, in biowarfare, **607-618**  
 availability of, 614-615  
 categories of, 607-612  
 cytokines, 607-610  
 dangers of, 612-615  
 dissemination of, 613-614  
 eicosanoids, 610  
 hormones, 610-611  
 limitations of, 612  
 neurotransmitters, 610-611  
 plasma proteases, 611-612  
 rapid action of, 612-613  
 stealth factor of, 612
- Biorex method, for glycohemoglobins,  
 60-61
- Biosensors, for biowarfare agents, 686-687
- Biosite Triage test, for cardiac markers, 355
- Biotin, red blood cells labeled with, for  
 survival studies, flow cytometric  
 detection of, 834-835
- Biowarfare  
 agriculture-directed, **549-591**  
 bioregulators in, **607-618**  
 chemicals in. *See* Toxins, in biowarfare.  
 defense against. *See* Biowarfare, protec-  
 tion against.  
 domestic animal-targeted, **549-591**  
 epidemiology of, 460-463  
 genomics in, **619-629**, 681, 686  
 goals of, 424  
 governmental response to, 465-466  
 health system response to, 436, 460-463  
 history of, **421-434**  
   casualties in, 422-423  
   dateline for, 421-423  
   in United States, 424-428  
 hoaxes in, 463-465  
 infectious pathogens in, 595. *See also* spe-  
 cific pathogens and diseases.  
 arthropod-transmitted, **495-512**  
 clinical features of, **435-473**  
 clinicopathologic aspects of, **513-548**  
 countries developing, 411-412
- decontamination of, 432, 663
- detection of  
 advanced research on, 684-687  
*Bacillus anthracis*, 643-644, 668-669,  
 672  
*Brucella*, 644, 668-669  
*Burkholderia*, 644-645, 668-669  
*Chlamydia psittaci*, 645  
*Clostridium botulinum*, 645-646, 665  
*Coxiella burnetii*, 646  
 culture in, 426, 428, 667-670  
 DNA-based, 643  
 fluorescent probe technology in,  
 636-642  
*Francisella tularensis*, 646  
 gene amplification methods for,  
 670-673  
 immunoassays for, 673-674  
 integrated diagnostic system for,  
 663, 666  
 laboratory-on-a-chip technology in,  
 642-643  
 methods for, **631-660**, **661-678**  
 molecular targets for, 643-650  
 polymerase chain reaction in, 634-  
 639  
 reporter dyes for, 639  
 safety in, 631-632, 662-663  
 signal amplification in, 642  
 specimen handling for, 632-634, 663,  
 667  
*Staphylococcus aureus*, 646, 665  
 viruses, 647-650  
*Yersinia pestis*, 647
- dispersion of, 436
- emerging, 414-416, 422
- laboratory accidents and, 412
- laws concerning, 413-414
- most dangerous, 413
- production of, 426
- re-emerging, 415-416
- recent challenges in, **411-420**
- stealthy nature of, 413
- subtypes of old agents, 415
- therapy-induced, 416
- treatment of, **435-473**
- viral. *See* Viral infections, in biowarfare.
- work with, safety measures for, 417-  
 418, 428
- munitions for, 428-430
- protection against, 412-413, 430-433,  
**679-689**
- diagnostic methods research for, 684-  
 687
- genetically engineered agents, 681
- research on, 680-681
- vaccines, 431-432, 484-485, 598, 681-  
 684
- threats of, 463-465, 679-680

## Biowarfare (Continued)

- toxins in. *See* Toxins, in biowarfare.
- warning systems for, 432-433
- Biowarfare Breathyalyzer, 686
- Birds
  - avian influenza in, 562-571
  - Newcastle disease of, 579-585
- Blood
  - bacterial identification in, flow cytometry in, 899-900
  - occult, point-of-care testing for, 395-398
  - typing of, red cell flow cytometry in, 833-834
- Blood gases, point-of-care testing for, 321-335
  - accuracy of, 326-328
  - cost issues in, 322-326
  - devices for, 325-326
  - documentation of, 328-330
  - implementation of, 333-334
  - options for, 322
  - quality assurance in, 330-333
- Blood transfusions
  - multiple, phenotyping after, flow cytometry in, 834
  - point-of-care testing during, 296-297
- Bolivian hemorrhagic fever, in biowarfare, 440, 452-455
- Bone marrow transplantation, in hyper IgM syndrome, flow cytometry after, 788-789
- Botulinum toxin, in biowarfare, 441, 455-457, 596-598, 645-646, 665
- Bradykinin, in biowarfare, 611
- Breast cancer, flow cytometry in, DNA and cell cycle analysis in, 875-895
  - historical background of, 876-878
  - prognostic model for, 879-893
- Breath tests
  - for alcohol, 369-370
  - for *Helicobacter pylori*, 401
- Breathyalyzer, Biowarfare, 686
- Bromodeoxyuridine, for proliferation assays, 851
- Brucellosis, in biowarfare, 438, 442-444, 540-544, 664
  - detection methods for, 644, 668-669
- Bubonic plague, in biowarfare, 526
- Burkholderia*, in biowarfare, 664
  - detection methods for, 644-645, 668-669
- C peptide
  - measurement of, in hypoglycemia, 90
  - suppression of, in fasting tests, 93
- C-reactive protein, point-of-care testing for, 298
- Calcium
  - flux of, in cell activation, flow cytometry in, 782-784

- intraoperative point-of-care testing for, medical outcome impact of, 296
- California encephalitis complex, in biowarfare, 497, 501-502
- Cancer
  - colorectal, occult blood testing for, 395-398
  - flow cytometry in, 706-708
  - breast, 875-895
  - treatment of, cytokines in, 798-799
- Capsular drop lesion, in diabetic nephropathy, 121
- Carbohydrates, intrinsic glycation potential for, 54
- Carboxyethyl lysine, 57
  - identification of, 69
  - in diabetic complications, 58
- Carboxymethyl lysine, 57
  - in diabetic complications, 58
- Cardiac markers, point-of-care testing for, 351-362
  - clinical studies of, 356-358
  - cost issues in, 358-359
  - rationale for, 351-353
  - systems for, 353-356
- Cardiothoracic surgery, point-of-care testing in, cost issues in, 276-277
- Cardiovascular disease, in diabetes mellitus, lipoprotein abnormalities and, 159-162
- Carpenter and Coustan criteria, for gestational diabetes mellitus, 177-181
- Casts, urine, point-of-care testing for, 384, 392
- Cattle, foot-and-mouth disease of, 553-562
- CD2, flow cytometric detection of, on lymphocytes, in lymphoproliferative disorders, 765
- CD3, flow cytometric detection of on lymphocytes, in lymphoproliferative disorders, 765
  - on T lymphocytes, in HIV infection, 845-846
- CD4, flow cytometric detection of on lymphocytes, in lymphoproliferative disorders, 765
  - on T lymphocytes after Hodgkin's disease radiation treatment, 703-706
- CD25 expression with, 772, 774
  - in atopy, 706
  - in HIV infection, 701, 703, 781, 842-845
  - in leprosy, 706
- CD5, flow cytometric detection of, on lymphocytes, 766
  - in lymphoproliferative disorders, 764, 769-772
- CD8, flow cytometric detection of on natural killer cells, 766

- on T lymphocytes
  - after Hodgkin's disease radiation treatment, 703-706
  - in atopy, 706
  - in cancer, 706-708
  - in HIV infection, 701, 703, 781, 843-846
  - in leprosy, 706
- CD8<sup>dull</sup>, flow cytometric detection of, on T lymphocytes, in Hodgkin's disease, 703-706
- CD10, flow cytometric detection of, on lymphocytes, in lymphoproliferative disorders, 765
- CD11a, flow cytometric detection of, on T lymphocytes
  - in leprosy, 706
  - naive, 701-702
- CD11b, flow cytometric detection of
  - in neoantigen expression, 787
  - on stem cells, in myelodysplastic syndrome, 819
- CD13, flow cytometric detection of, on lymphocytes, in leukemia, 765
- CD16, flow cytometric detection of, on stem cells, in myelodysplastic syndrome, 819-820
- CD19, flow cytometric detection of, on T lymphocytes, in HIV infection, 846
- CD20, flow cytometric detection of, on B lymphocytes, 766
- CD22, flow cytometric detection of, on lymphocytes, in lymphoproliferative disorders, 764
- CD23, flow cytometric detection of, on lymphocytes, in lymphoproliferative disorders, 764
- CD25, flow cytometric detection of, on T lymphocytes, 766, 772-774
  - in HIV infection, 846
- CD27, flow cytometric detection of, on T lymphocytes, naive, 701-702
- CD28, flow cytometric detection of, on T lymphocytes, in HIV infection, 846
- CD34, flow cytometric detection of
  - on lymphocytes, in lymphoproliferative disorders, 765
  - on stem cells, in myelodysplastic syndrome, 814, 817-819
- CD38, flow cytometric detection of, on T lymphocytes, 773-774
  - in HIV infection, 843, 846
  - quantitative, 755
- CD40 ligand (CD154), flow cytometric detection of, in hyper IgM syndrome, 787-789
- CD45, flow cytometric detection of, on T lymphocytes, in HIV infection, 845-846
- CD45RA, flow cytometric detection of, on T lymphocytes, 773-774
  - in leprosy, 706
  - naive, 701-702
- CD62L, flow cytometric detection of, on T lymphocytes
  - in leprosy, 706
  - naive, 701-702
- CD69, flow cytometric detection of, on lymphocytes, in neoantigen expression, 786-787
- CD79b, flow cytometric detection of, on lymphocytes, in lymphoproliferative disorders, 764-765
- CD95, flow cytometric detection of, on T lymphocytes, 773-774
- CD154, flow cytometric detection of, in hyper IgM syndrome, 787-789
- CD163, flow cytometric detection of, on monocytes, 835
- Cell(s), division of, flow cytometry in, 790-792
- Cell cycle and cell death. *See also* Apoptosis.
  - cytometry in, 857-873
  - cyclin expression in, 860-866
  - in breast cancer. *See* Breast cancer, flow cytometry in.
  - laser scanning, 858-860, 869-871
  - multivariate gating analysis in, 864-866
- Cell surface receptors, aggregation of, flow cytometry studies in, 780
- Cellular immunity, in diabetes mellitus, 23-25
- Cellulose tape method, for pinworm collection, 381
- Cesarean delivery, in gestational diabetes mellitus, 185-186
- Chemical Warfare Convention, 595
- Chemokines and chemokine receptors, flow cytometric detection of, 766-767
- Chest pain, point-of-care testing in. *See also* Cardiac markers, point-of-care testing for.
  - medical outcome impact of, 295
- Chickens
  - avian influenza in, 562-571
  - Newcastle disease of, 579-585
- Chlamydia psittaci*, in biowarfare, detection methods for, 645
- Chlorpropamide, liver disease due to, 197-198
- Cholera, hog, in biowarfare, 571-578
- Cholesterol, excess of. *See* Lipid(s), profile of, in diabetes mellitus.
- Chromatography
  - for drug testing, 365-366
  - for glycohemoglobins, 59-62
- Chromium-51, red blood cells labeled with, for survival studies, 834-835
- Chromosomal abnormalities, of myelodysplastic syndrome, 821-822

- Chronic granulomatous disease, flow cytometry in, 784-785
- Chylomicrons, excess of, in diabetes mellitus, 151-153
- Cidofovir, for viral infections, 488
- Cirrhosis
- coagulation point-of-care testing in, 344
  - diabetes mellitus and, 199-201
- Classic swine fever, in biowarfare, 571-578
- Clinical cytokine network cytometry, 795-809
- biologic considerations in, 796-797, 803-804
  - cells of interest in, 801
  - clinical relevance of, 797-799
  - cytokine of interest in, 800-801
  - definition of, 795
  - functional assays in, 802
  - in leukemia, 804-805
  - in lymphoma, 805-806
  - in Sézary's syndrome, 805-806
  - multidimensional approach to, 799-802
  - receptors of interest in, 802
  - technical considerations in, 804
- Clinical Laboratory Improvement Amendment
- certificate of, possession of, 256-257
  - inspection requirements of, 244-246
  - on point-of-care testing, 218, 232-234
  - waived category, 242-243, 245
  - test classification of, 242-243
- Clostridium botulinum* toxin, in biowarfare, 441, 455-457, 596-598, 645-646, 665
- Clothing, for biowarfare agent protection, 431
- CoaguChek devices, 338-341, 344, 346
- Coagulation disorders, in insulin resistance syndrome, 38
- Coagulation factors, in biowarfare, 611-612
- Coagulation testing, point-of-care, 337-350
- activated clotting time, 346-348
  - activated partial thromboplastin time, 345-346
  - advantages of, 337
  - disadvantages of, 337
  - in operating room, 276-277
  - medical outcome impact of, 293-294
  - platelet function, 348
  - prothrombin, 338-345
- Cold-tolerant organisms, 623-624
- College of American Pathologists
- guidelines of, for point-of-care testing, 252-253
  - test classification of, 243-244
- Colorado tick fever, in biowarfare, 497, 502
- Colorectal cancer, occult blood testing for, 395-398
- Coltivirus infections, in biowarfare, 497, 502
- Computer systems, for point-of-care testing data management, 264-266
- Congestive heart failure, cytokine imbalance in, 799
- Coronary syndromes, acute, point-of-care testing in. *See* Cardiac markers, point-of-care testing for.
- Cortisol
- excess of, diabetes mellitus in, 4
  - measurement of, in hypoglycemia, 92
- Cost issues, in point-of-care testing, 226, 234, 269-284
- acute, 322-326
  - cardiac markers, 358-359
  - emergency department, 274-276
  - glucose, 272-274, 316
  - hospital operations impact, 279-282
  - labor cost savings, 278-279
  - non-reagent, 325
  - operating room, 276-277
- Coumatrak device, 338-339, 342-343
- Coxiella burnetii* infections (Q fever), in biowarfare, 439, 445-446, 534-540, 646
- Creatine kinase, point-of-care testing for. *See* Cardiac markers, point-of-care testing for.
- Crimean-Congo hemorrhagic fever, in biowarfare, 440, 452-455, 481, 497, 502
- clinical features of, 478-479
- Crops, as biowarfare targets, 550, 552
- Crystals, urine, point-of-care testing for, 392
- Culture, of biowarfare pathogens, 426, 428, 667-670
- Cyclins, in cell cycle and cell death, measurement of, flow cytometry in, 860-866
- Cytogenetics, of myelodysplastic syndrome, 821-822
- Cytokines. *See also specific cytokines.*
- biology of, 796-797, 803-804
  - excess of, in myelodysplastic syndrome, 815
  - in beta cell destruction, 16, 23-25
  - in biowarfare, 607-610
  - monitoring of. *See also* Clinical cytokine network cytometry.
  - intracellular, in HIV infection, 847-850
  - therapeutic use of, 798-799
- Cytometric bead array technology. *See* Suspension array technology.
- Cytometry, flow. *See* Flow cytometry.
- Cytoplasmic vacuolization, in diabetic nephropathy, 121-123
- Cytotoxic T-lymphocyte adhesion ligand, polymorphisms of, in diabetes mellitus, 19
- D-antigen mismatch, fetomaternal hemorrhage and, 830-831

- Dade-Behring Stratus CS test, for cardiac markers, 356
- Data management, in point-of-care testing, 264-266  
glucose, 315-316  
in acute testing, 328-330
- DCA2000 assay, for glycohemoglobins, 61-62
- Death, from hypoglycemia, 95
- Deemed status, for laboratory inspections, 245, 257
- Deer fly fever (tularemia), in biowarfare, 439, 447, 529-534, 646, 665
- Defense Advanced Research Projects Agency, 680-681, 684-685
- Deinococcus radiodurans*, in biowarfare, 624-627
- Dengue hemorrhagic fever, in biowarfare, 480, 496, 499
- 3-Deoxyglucosone, as glycation agent, 55-56  
in diabetic complications, 58  
measurement of, 70-71
- Desiccation, organisms resistant to, in biowarfare, 624
- Diabetes mellitus  
adult-onset. *See* Diabetes mellitus, type 2.  
classification of, 1-13. *See also specific types.*  
old terms in, 1  
summary of, 12-13  
complications of. *See also* Nephropathy, diabetic.  
gestational, 181-183  
glycated proteins in, 57-59, 65-67  
retinopathy, 58  
vasculopathy, 58, 65-66  
definition of  
gestational, 5-7, 173  
type 1, 2  
type 2, 2-3  
uncontrolled, 99  
diagnosis of  
criteria for, 7-8  
gestational, 6-7, 177-181  
glycated proteins in, 71  
type 1, 21-23  
drug-induced, 4-5  
genetic factors in  
beta cell defects, 3-4  
in nephropathy, 133  
insulin resistance and, 31-32, 34  
syndromes, 5  
type 1, 17-20  
type 2, 31-32  
gestational. *See* Gestational diabetes mellitus.  
glucose monitoring in. *See* Glucose, point-of-care testing for.  
glycated proteins in, 53-78, 140, 185  
in beta cell abnormalities. *See* Beta cells.  
in endocrinopathies, 4  
in genetic syndromes, 5  
in insulin action genetic defects, 4  
in insulin resistance syndrome, 5  
in obesity, 3  
in pancreatic disease, 4  
in stiff-man syndrome, 5, 21  
in viral infections, 5  
insulin-dependent. *See* Diabetes mellitus, type 1.  
juvenile. *See* Diabetes mellitus, type 1.  
lipid disorders in, 147-172  
liver disease and, 193-207  
malnutrition-based, as outmoded term, 1  
maturity-onset diabetes of the young, 3-4, 34-35  
nephropathy in, 58, 111-145  
non-insulin-dependent. *See* Diabetes mellitus, type 2.  
pathogenesis of, type 1, 25-26  
pathophysiology of  
gestational, 174-175  
uncontrolled, 100  
risk factors for, gestational diabetes mellitus and, 186-187  
screening for, 7-8  
gestational, 175-177  
terminology of, 1  
treatment of  
gestational, 183-187  
liver disease due to, 197-198  
nephropathy and, 134, 137  
uncontrolled, 106-107  
type 1  
definition of, 2  
idiopathic, 2  
immune-mediated, 15-30  
cellular immunity in, 23-25  
definition of, 2  
diagnosis of, 21-23  
environmental factors in, 17-20  
genetic factors in, 17-20  
historical background of, 15  
islet cell autoantibodies in, 20-21  
islet cell destruction in, 15  
natural history of, 22  
pathogenesis of, 25-26  
preclinical period of, 15-16  
prediction of, 21-23  
immunopathology of, 15-30  
lipid disorders in. *See* Lipid(s), profile of, in diabetes mellitus.  
uncontrolled, 101-102  
type 2, 31-51  
causes of, 34-36  
clinical features of, 36-38  
definition of, 2-3  
environmental factors in, 31-32, 34-35



- Diabetes mellitus (*Continued*)  
 genetic factors in, 31-32  
 insulin resistance in. *See* Insulin, resistance to.  
 laboratory assessment of, 42-45  
 lipid disorders in. *See* Lipid(s), profile of, in diabetes mellitus.  
 uncontrolled, 101-102  
 uncommon causes of, 5  
 uncontrolled, **99-110**  
   continuum of, 99  
   definition of, 99  
   diagnosis of, 100-106  
   pathophysiology of, 100  
   precipitating factors for, 100  
   prevalence of, 99-100  
   treatment of, 106-107  
   type 1, 2  
   type 2, 3  
 Diabrac glycosylated hemoglobin method, 62  
 "Diagnostic bed," 321  
 Dialysis, in diabetic nephropathy, 139  
 Diamat method, for glycohemoglobins, 62  
 Dicarboxyl inhibitors, in glycated protein control, 69-70  
 Diet, in diabetes mellitus, 164  
   gestational, 184  
 Dipstick urinalysis, 389-395  
 Direct agglutination test, flow cytometry in, 834  
 Diuretics, in diabetic nephropathy, 138-139  
 DNA  
   disintegration of, in myelodysplastic syndrome, 814-815  
   synthesis of, in lymphocytes, flow cytometry in, 788, 790  
 DNA analysis  
   in breast cancer. *See* Breast cancer, flow cytometry in.  
   in myelodysplastic syndrome, 814  
   in pathogen detection, 643  
   microspheres in, 732  
 Drugs  
   diabetes mellitus due to, 4-5  
   point-of-care testing for  
     in drug abuse, **363-374**  
       advantages of, 372  
       alcohol, 369-370  
       confirmation of, 365  
       devices for, 367-369  
       disadvantages of, 372-373  
       in toxicity, 365-367  
       specimens for, 366  
       types of, 364-365  
       versus central laboratory methods, 370-371  
   in therapeutic monitoring, 293, 369  
 Dyslipidemia, in insulin resistance syndrome, 37-38  
 Eastern equine encephalitis, in biowarfare, 440, 450-452, 480, 496  
   detection methods for, 648  
   taxonomy of, 499  
 Ebola virus infections, in biowarfare  
   clinical features of, 478-479, 481  
   detection methods for, 650  
   outbreaks of, 476  
 Eggs, pinworm, microscopic detection of, 380-382  
 Eicosanoids, in biowarfare, 610  
 Elderly persons  
   diabetic nephropathy in, 135  
   insulin resistance in, 33  
 Electrolytes, point-of-care testing for, **321-335**  
   accuracy of, 326-328  
   cost issues in, 322-326  
   devices for, 325-326  
   documentation of, 328-330  
   implementation of, 333-334  
   options for, 322  
   quality assurance in, 330-333  
 Electron microscopy, in diabetic nephropathy, 125-127  
 Emergency department, point-of-care testing in  
   cost issues in, 274-276  
   drug abuse, 367  
   medical outcome impact of, 294-295  
 Encephalitis, viral, in biowarfare, 440, 450-452, 496-497  
   animal models for, 485-486  
   clinical features of, 477-478, 480  
   detection methods for, 502-508, 648-649, 665, 669  
   diagnosis of, 480, 486-487  
   immune response to, 484  
   outbreaks of, 476  
   pathology of, 480, 482  
   surveillance for, 508-509  
   targets of, 480, 483  
   taxonomy of, 498-502  
 Endothelins, in diabetic nephropathy  
   pathogenesis, 131-132  
*Enterobius vermicularis* (pinworm),  
   microscopic detection of, 380-382  
 Enterotoxins, staphylococcal, in  
   biowarfare, 441, 457-459, 598-599, 646, 665  
 Environmental factors, in diabetes mellitus, 17-20, 31-32, 34-35  
 Enzymatic amplification staining, in flow cytometry, **763-778**  
   for CD5 detection  
     on CD4 T lymphocytes, 772, 774  
     on neoplastic B lymphocytes, 769-772  
   need for, 764-767  
   principles of, 768-769  
 Enzyme-linked immunosorbent assay, for  
   biowarfare agents, 506-507, 673-674



- Epinephrine  
 excess of, diabetes mellitus in, 4  
 in biowarfare, 611
- Epithelial cells, urine, point-of-care testing for, 392
- Estrogen receptor, binding of, microsphere-based molecular cytometry studies of, 733, 735-736
- Euglycemic hyperinsulinemic glucose clamp technique, for insulin resistance evaluation, 38-40
- Exercise  
 in lipid disorders, in diabetes mellitus, 164-165  
 reduced, insulin resistance in, 34
- Extremophiles, in biowarfare, **619-629**  
 advantages of, 626-627  
 attributes of, 621-622  
 cold-tolerant, 623-624  
 desiccation-resistant, 624  
 heat-tolerant, 623  
 pressure-resistant, 623  
 radiation-resistant, 624-626  
 types of, 622-626
- F cells, enumeration of, flow cytometry in, 831-833
- Fasting tests, for hypoglycemia, 93
- Fatty acids, free, excess of  
 in diabetes mellitus, 194  
 insulin resistance in, 32-33, 36
- Feces. *See* Stool.
- Fenofibrate, in hypertriglyceridemia, in diabetes mellitus, 167
- Fern test, 378
- Fetomaternal hemorrhage, detection of, red cell flow cytometry in, 830-831
- Fibrin caps, in diabetic nephropathy, 121
- Fish oils, in hypertriglyceridemia, in diabetes mellitus, 167
- Flow cytometry  
 cytokine network, **795-809**  
 eleven-color  
 development of, 698-699  
 in anergy, in cancer, 708-709  
 in antigen-specific T lymphocyte identification, in cancer, 708-709  
 in atopy, 706-708  
 in Hodgkin's disease, after radiation therapy, 703-706  
 in immune system evaluation, **697-712**  
 in interferon-g-polarized T lymphocyte identification, 706-708  
 in interleukin-4-polarized T lymphocyte identification, 706-708  
 in leprosy, 706-708  
 in naive T-lymphocyte identification, 700-706  
 enzymatic amplification staining in, **763-778**  
 fluorescent dyes for, in microbiology, 900-902  
 in anergy in cancer, 708-709  
 in apoptosis, 867-871  
 in atopy, 706-708  
 in breast tumor prognosis, **875-895**  
 in cell cycle and cell death studies, **857-873**  
 in functional assays, **779-794**  
 calcium flux, 782-784  
 cell surface aggregation, 780  
 in cytokine network monitoring, 802  
 neoantigen appearance, 786-789  
 oxidative metabolic changes, 784-785  
 proliferation, 788, 790-792, 851-853  
 transcription factor activation, 785-786  
 tyrosine phosphorylation, 780-782  
 in Hodgkin's disease, after radiation therapy, 703-706  
 in human immunodeficiency virus infection assays, **841-856**  
 in hyper IgM syndrome, 787-789  
 in immunology. *See* Immunology, flow cytometry in.  
 in interferon-g-polarized T-cell subset identification, 706-708  
 in interleukin-4-polarized T-cell subset identification, 706-708  
 in leprosy, 706-708  
 in leukemia, 764-766, 769, 771-772, 804-805  
 in lymphoma, 764-766, 769-772, 805-806  
 in microbiology, **897-909**  
 in myelodysplastic syndrome, **811-828**  
 in naive T-lymphocyte identification, 700-706  
 in Sézary's syndrome, 805-806  
 laser scanning, in cell cycle and cell death, 858-860, 869-871  
 molecular, microsphere-based, **731-742**  
 multicolor. *See* Flow cytometry, eleven-color.  
 multiplexing in  
 in microbiology, 902-904  
 with suspension array technology, 722-723  
 quantitative. *See* Quantitative flow cytometry.  
 red cell, **829-840**  
 sample handling and processing for in microbiology, 899-900  
 in suspension array technology, 724-725  
 suspension array technology in, **713-729**, 849-850  
 tetramer assay in, 846-847, 850  
 Fluid replacement, in uncontrolled diabetes mellitus, 106

- Fluorescent probe technology, for  
polymerase chain reaction, in  
biowarfare agent detection, 636-642
- Fluorochromes, for flow cytometry,  
767-768  
in calcium flux studies, 782-784
- Fluorospheres, for suspension array  
technology, 714, 720
- Foot-and-mouth disease, in biowarfare,  
553-562  
clinical features of, 556-557  
control of, 561  
definition of, 553  
diagnosis of, 560-561  
differential diagnosis of, 560  
epidemiology of, 555-556  
etiology of, 554  
geographic distribution of, 554-555  
hosts for, 554  
incubation period of, 556  
morbidity and mortality in, 559  
pathology of, 557-559  
public health implications of, 561-562  
transmission of, 555-556
- Forensic considerations, in hypoglycemia,  
95
- Francisella tularensis* infections (tularemia),  
in biowarfare, 439, 447, 529-534, 646,  
665
- Free radicals, diabetic nephropathy and,  
130
- Fructosamines, diabetes mellitus and,  
gestational, 185
- Functional status, as outcome measure,  
286-288
- Gastric fluid, occult blood in, point-of-care  
testing for, 397-398
- Gastritis, *Helicobacter pylori*, point-of-care  
testing for, 298, 399-401
- Gastrointestinal tract, occult blood testing  
in, 395-398
- GEM Portable Coagulation Laboratory, 341
- Gemfibrozil, in lipid disorders, in diabetes  
mellitus, 161-162, 167
- Genetic factors, in diabetes mellitus. *See*  
Diabetes mellitus, genetic factors in.
- Genomics, in biowarfare agent  
development and detection, 619-629,  
681, 686
- Gestational diabetes mellitus, 173-190  
complications of, 181-183  
definition of, 5-7, 173  
diagnosis of, 177-181  
epidemiology of, 173  
glucose monitoring in, medical outcome  
impact of, 292-293  
historical perspective of, 173-174  
pathophysiology of, 174-175  
screening for, 175-177  
treatment of  
antepartum, 183-185  
peripartum, 185-186  
postpartum, 186-187
- Glomerular basement membrane,  
abnormalities of, in diabetes mellitus,  
125-126, 132-133
- Glomerular filtration rate, diabetic  
nephropathy and, 134
- GLORIA (Gold Labelled Optically Read  
Immunoassay), for troponin, 354-355
- Glucagon  
deficiency of  
hypoglycemia in, 81  
in diabetes mellitus, 23  
excess of, diabetes mellitus in, 4, 100,  
201  
measurement of, in hypoglycemia, 92
- Glucagon-like-peptide-1, in hyperglycemic  
clamp test, 44
- Gluconeogenesis  
in fatty acid excess, 194  
inhibition of, hypoglycemia in, 82
- Glucose  
deficiency of. *See* Hypoglycemia.  
excess of. *See* Hyperglycemia.  
homeostasis of, 81-82  
intolerance of, in pregnancy. *See* Gestational diabetes mellitus.  
measurement of  
in gestational diabetes mellitus, 183-  
184  
in hypoglycemia, 87-88  
venous versus arterial blood for, 88  
metabolism of  
in cirrhosis, 201  
in liver, diabetes mellitus and, 193-194  
point-of-care testing for, 305-319  
accuracy of, 310-313  
applications of, 305-306, 316-317  
calibration of, 308  
comparison with central laboratory re-  
sults, 307  
cost issues in, 272-274, 316  
data management in, 315-316  
device problems in, 314-315  
environmental effects on, 313-314  
evolution of, 224-226  
goals of, 306-307  
home versus hospital, 306-314  
in urine, 391  
linearity of, 313  
medical outcome impact of, 290-293,  
316  
methodologies for, 308-310  
organizational issues in, 314-315  
precision of, 312-313  
quality assurance of, 229-232

- sample recovery in, 312
- specimen selection for, 312
- tolerance limits for, 311
- protein reactions with. *See* Glycated proteins.
- toxicity of, insulin resistance in, 36
- transport of, 80-81
- Glucose challenge test, in gestational diabetes mellitus, 177
- Glucose clamp technique, for insulin resistance evaluation, 38-40
- Glucose dehydrogenase method, for glucose testing, 310
- Glucose model analysis, continuous infusion
  - in beta cell dysfunction, 45
  - in insulin resistance, 42
- Glucose oxidase method, for glucose testing, 308-310
- Glucose tolerance test
  - in beta cell function evaluation, 43, 45
  - in gestational diabetes mellitus, 177-181
  - in insulin resistance, 41
- Glutamic acid decarboxylase, antibodies to, in diabetes mellitus, 20-22
- Glycated proteins, 53-78
  - advanced end products of, 56-58, 70-71
  - chemistry of, 53-57
  - clinical significance of, 64-68
  - control of, 69-70
  - defense mechanisms against, 69
  - derivatives of, 56-57
  - detoxification of, 56
  - diabetic complications due to, 57-58, 65-67
  - fructosamines, 53-54, 63-65, 185
  - future research and clinical applications for, 68-71
  - glycohemoglobins, 59-63
  - identification of, 69
  - in early diagnosis of diabetes mellitus, 71
  - in nephropathy, 130-131
  - inhibitors of, in diabetic nephropathy, 140
  - intracellular versus extracellular, 68
  - intrinsic potential for, 54
  - measurement of
    - fructosamines, 63-65, 185
    - glycohemoglobins, 59-63, 65-68
    - in long-term diabetes mellitus control evaluation, 64
    - in transient postprandial hyperglycemic episodes, 67-68
  - nonglucose agents in, 68-69
- Glyoxal, as glycation agent, 55-56
- Goats, foot-and-mouth disease of, 553-562
- Gold Labelled Optically Read
  - Immunoassay, for troponin, 354-355
- Granulocytes, oxidative metabolism of, flow cytometry in, 784-785
- Growth factors, in biowarfare, 609
- Growth hormone
  - excess of, diabetes mellitus in, 4, 201
  - measurement of, in hypoglycemia, 92
- Guanidines, in glycated protein control, 69-70
- Hairpin primers, for polymerase chain reaction, 639
- Hand-foot-mouth disease, 561-562
- Hantavirus infections, in biowarfare, 497, 502, 650
- Health Care Finance Administration, inspection requirements of, 243, 245, 257
- Heat-tolerant organisms, in biowarfare, 623
- Helicobacter pylori*, point-of-care testing for, 298, 399-401
- Hematopoiesis, defects of, in myelodysplastic syndrome, 811-816
- Hematuria, point-of-care testing for, 383, 391-392
- Hemochromatosis, diabetes mellitus and, 199
- Hemochron Jr. Signature device, 341
- Hemodialysis, in diabetic nephropathy, 139
- Hemodynamic theory, of diabetic nephropathy, 132
- Hemoglobin(s)
  - fetal, cells containing (F cells), enumeration of, flow cytometry in, 831-833
  - glycated, 59-63, 65-68
  - in gastrointestinal tract, point-of-care testing for, 395-398
- Hemoglobin F, antibody to, in fetomaternal hemorrhage detection, 831
- Hemolytic anemia, autoimmune, red cell flow cytometry in, 834
- Hemorrhage, fetomaternal, detection of, red cell flow cytometry in, 830-831
- Hemorrhagic fever(s), viral, in biowarfare, 440, 496-497
  - clinical features of, 478-481
  - detection methods for, 649-650, 665
  - diagnosis of, 480-481, 486-487
  - immune response to, 485
  - laboratory diagnosis of, 502-508
  - outbreaks of, 476
  - pathology of, 480-482
  - surveillance for, 508-509
  - targets of, 480-484
  - taxonomy of, 498-502
- Hemorrhagic fever with renal syndrome, in biowarfare, 481
- Hepatitis C, diabetes mellitus and, 198-199
- Hexokinase method, for glucose testing, 310

- HIV infection. *See* Human immunodeficiency virus infection.
- Hodgkin's disease, radiation therapy for, flow cytometry in, 703-706
- Hog(s)  
foot-and-mouth disease of, 553-562  
swine fever in, 571-578
- Hog cholera, in biowarfare, 571-578
- Home testing  
for coagulation, 339, 342-343  
for glucose  
medical outcome impact of, 290-293  
versus hospital testing, 306-314  
for pregnancy, 402-403  
future of, 236-237  
history of, 219
- Homeostasis model analysis  
in beta cell dysfunction, 44  
in insulin resistance, 41-42
- Hormones, in biowarfare, 610-611
- Horseradish peroxidase, in amplification staining, in flow cytometry, 768-769
- Human chorionic gonadotropin, detection of, in pregnancy testing, 402-403
- Human immunodeficiency virus infection  
flow cytometry in, 841-856  
absolute cell counting, 843, 845  
apoptosis assays, 850  
CD4 lymphocyte measurement, 842-845  
cell-associated virus quantitation, 850-851  
cytokine assays, 847-850  
multicolor immunophenotyping, 844-846  
proliferation assays, 851-853  
quantitative, 752-754, 846  
tetramer assay, 846-847, 850  
tyrosine phosphorylation assessment, 781  
treatment of, cytokines in, 798-799  
viral RNA measurement in, 842-843, 850-851
- Human leukocyte antigens  
in diabetes mellitus, 2, 17-20  
in myelodysplastic syndrome, 812, 819, 821, 823
- Hyalinosis, in diabetic nephropathy, 121, 124, 127
- b-Hydroxybutyrate, measurement of  
in hypoglycemia, 88-89  
in uncontrolled diabetes mellitus, 103-104
- Hyper IgM syndrome, neoantigen expression in, flow cytometry in, 787-789
- Hyperchloremic metabolic acidosis, in uncontrolled diabetes mellitus, 105
- Hypercholesterolemia. *See* Lipid(s), profile of, in diabetes mellitus.
- Hyperchylomicronemia, in diabetes mellitus, 151-153
- Hyperglycemia  
diabetic complications due to, 66-67  
fetal, in gestational diabetes mellitus, 182-183, 186  
glycohemoglobin assay in, 64  
in uncontrolled diabetes mellitus. *See* Diabetes mellitus, uncontrolled.  
pathogenesis of, in diabetes mellitus, type 2, 36-38  
postprandial, glycohemoglobin and, 67-68  
treatment of, lipid profile and, 165-166
- Hyperglycemic clamp technique, in beta cell function evaluation, 43-44
- Hyperinsulinemia  
fetal, in gestational diabetes mellitus, 182, 186  
hypoglycemia in, 81-82, 93  
in cirrhosis, 200  
in glucose clamp technique, 38-40  
in insulin resistance syndrome, 37
- Hyperkalemia, in diabetic nephropathy, 139
- Hyperlipidemia, in diabetes mellitus, 194-195. *See also* Lipid(s), profile of, in diabetes mellitus.  
postprandial, 154-155
- Hypermagnesemia, in uncontrolled diabetes mellitus, 106
- Hypermnatremia, in uncontrolled diabetes mellitus, 105
- Hyperphosphatemia, in uncontrolled diabetes mellitus, 106
- Hypertension  
in diabetes mellitus, in nephropathy, 133-134, 137-138  
in insulin resistance syndrome, 37  
pregnancy-induced, diabetes mellitus and, 181-182
- Hyperthermophiles, in biowarfare, 623
- Hypertriglyceridemia, in diabetes mellitus, 149, 151-153, 194-195  
postprandial, 154-155  
treatment of, 167-168
- Hypoglycemia, 79-97  
alcohol-induced, 82, 89  
biopsy in, 94  
causes of, 83, 85  
clinical features of, 79-81  
confirmation of, 87-89  
definition of, 79  
dynamic function tests in, 92-93  
fasting tests in, 93  
forensic considerations in, 95  
glucose homeostasis and, 81-82  
histopathology of, 94  
hormone assay techniques in, 89-92  
insulin-like growth factors in, 82-83, 91-92

- investigation of, 83-87
- meal-induced, 93-94
- neonatal, in gestational diabetes mellitus, 183, 186
- spontaneous, 79
- syndromes of, 79-80
- unawareness of, 80
- Hypokalemia, in uncontrolled diabetes mellitus, 105, 107
- Hyponatremia, in uncontrolled diabetes mellitus, 105
- IMD genes, defects of, in diabetes mellitus, 17
- Immune response, in viral infections, 484-485
- Immunoassays
  - for biowarfare agents, 646, 673-674
  - for drugs of abuse, interpretation of, 371
  - for glycohemoglobins, 59-62
  - for troponin, 354-355
  - suspension array. *See* Suspension array technology.
- Immunodeficiency, in leukocyte adhesion deficiency, flow cytometry in, 787
- Immunofluorescence staining, in diabetic nephropathy, 125
- Immunoglobulin(s), bound to red cells, detection of, flow cytometry in, 834
- Immunology, flow cytometry in
  - cytokine network, 795-809
  - eleven-color, 697-712
    - in anergy in cancer, 708-709
    - in atopy, 706-708
    - in Hodgkin's disease, after radiation therapy, 703-706
    - in interferon-g-polarized T-cell subset identification, 706-708
    - in interleukin-4-polarized T-cell subset identification, 706-708
    - in leprosy, 706-708
    - in naive T-lymphocyte identification, 700-706
  - in HIV infection, 845-846
  - sensitivity enhancement in, 763-778
    - enzymatic amplification staining
      - method for, 768-774
      - future of, 774-775
      - methods for, 767-768
      - need for, 764-767
    - suspension array technology in. *See* Suspension array technology.
- Immunosuppressive therapy, diabetes mellitus and, 202
- IMx Glycated Hg method, 62
- Indirect immunofluorescence assay, for islet cell antibodies, 20
- Infants
  - low birth weight, insulin resistance and, 35-36
  - of diabetic mothers
    - complications in, 187
    - macrosomia in, 182-183, 185-186
- Infections
  - hypoglycemia in, 83
  - in biological warfare. *See* Biowarfare, infectious pathogens in; *specific pathogens and diseases.*
- Infertility, semen analysis in, 380
- Influenza, avian. *See* Avian influenza.
- Inspection, of laboratories, 243-246, 257
- Insulin
  - action of
    - genetic defects in, diabetes mellitus in, 4
    - in pregnancy, 174-175
    - on triglyceride-rich lipoproteins, 151-153
  - administration of
    - in diabetes mellitus
      - gestational, 184-185
      - uncontrolled, 106-107
    - malicious, 95
  - antibodies to, measurement of, in hypoglycemia, 92
  - deficiency of, in diabetes mellitus
    - type 1, 2
    - type 2, 2-3
    - uncontrolled, 100
  - excess of, hypoglycemia in, 81-82
  - in biowarfare, 611
  - measurement of, in hypoglycemia, 89-90
  - receptor for
    - antibodies to, measurement of, in hypoglycemia, 92
    - defects of, 4
    - dysfunction of, 34
  - resistance to, 31-51
    - causes of, 32-34
    - clinical features of, 36-38
    - drug-induced, 4-5
    - environmental factors in, 31-32
    - genetic factors in, 31-32, 34
    - in cirrhosis, 200
    - in pregnancy, 174
    - interferon-induced, 199
    - laboratory assessment of, 38-42
    - liver role in, 194
    - syndrome of, 37-38
    - triglyceride-rich lipoproteins in, 152-153
    - type A, 4
    - type B, 5
    - uncontrolled diabetes mellitus in, 100
  - sensitivity to, versus beta cell function, 45
- Insulin-like growth factors
  - excess of, in cirrhosis, 200
  - hypoglycemia and, 82-83, 91-92
- Insulin tolerance test, in insulin resistance, 40-41

- Insulinoma  
 antibodies to, 21  
 hypoglycemia in, 94  
 Insulinitis, 15, 23-25  
 Integrated diagnostic system, for  
   biowarfare agent detection, 663, 666  
 Intensive care unit, point-of-care testing in.  
   *See also* Acute care testing.  
   medical outcome impact of, 295-296  
 Interferon(s)  
   in beta cell destruction, 16  
   therapeutic use of, 798-799  
   for hepatitis C, diabetes mellitus and,  
   199  
   for viral infections, 488  
 Interferon-g  
   in biowarfare, 609  
   in T lymphocyte polarization, flow cy-  
   tometry and, 706-708  
 Interleukin(s)  
   biology of, 796-797  
   imbalance of, in Sézary's syndrome,  
   805-806  
   in beta cell destruction, 16  
   in biowarfare, 609  
   therapeutic use of, 798-799  
 Interleukin-4, in T lymphocyte  
   polarization, flow cytometry and,  
   706-708  
 International normalized ratio, for  
   anticoagulant monitoring, 338-339,  
   342-344  
 International sensitivity index, for  
   anticoagulant monitoring, 338  
 Intravenous glucose tolerance test, in beta  
   cell function evaluation, 43  
 Islet cells. *See also* Beta cells.  
   antibodies to, in diabetes mellitus, 20-22  
   tumors of, 21, 94
- Japanese encephalitis, in biowarfare, 480,  
 496, 499  
 Joint Commission on Accreditation of  
   Healthcare Organizations  
   control sample analysis requirements of,  
   262  
   inspection requirements of, 257  
   on point-of-care testing, 218, 232-234  
   waived category, 243  
   test classification of, 243  
 Junin virus infections, in biowarfare,  
 478-479  
 Juvenile diabetes mellitus. *See* Diabetes  
   mellitus, type 1.
- KB (visual microscopic counting) method,  
   for fetomaternal hemorrhage  
   detection, 830-831
- Ketoacidosis, diabetic. *See* Diabetes  
   mellitus, uncontrolled.  
 a-Ketoaldehyde, as glycation agent, 55  
 Ketones  
   in hypoglycemia, 88-89  
   measurement of, in uncontrolled diabe-  
   tes mellitus, 103-104  
 Ketonuria, point-of-care testing for, 391  
 Ki67 antigen, detection of, in flow  
   cytometric proliferation assays, 851  
 Kidney  
   diabetes mellitus effects on. *See* Nephrop-  
   athy, diabetic.  
   failure of, hypoglycemia in, 83  
   transplantation of, in diabetic nephrop-  
   athy, 139-140  
 Kimmelstiel-Wilson nodules, in diabetic  
   nephropathy, 114, 116, 118  
 Kinins, in biowarfare, 611  
 Kolmogorov-Smirnov test, 764  
 Korean hemorrhagic fever, in biowarfare,  
 440, 452-455
- La Crosse virus infections, in biowarfare,  
 501-502  
 Laboratory-on-a-chip technology, for  
   pathogen detection, 642-643  
 Laser scanning cytometry, in cell cycle and  
   cell death, 858-860, 869-871  
 Lasers, in suspension array technology,  
 715, 720-721  
 Lassa fever, in biowarfare, 440, 452-455,  
 478-479, 481  
 Legal issues, in biowarfare agents, 413-414  
 Length of stay, as outcome measure, 288  
 Leprosy, flow cytometry in, 703-706  
 Leukemia  
   flow cytometry in, 764-766, 769, 771-772  
   cytokine balance and, 804-805  
   myelodysplastic syndrome progression  
   to, 815-816  
   treatment of, cytokines in, 798  
 Leukocyte(s), point-of-care testing for  
   in stool, 377-378  
   in urine, 392  
 Leukocyte adhesion deficiency, flow  
   cytometry in, 787  
 Leukocyte esterase, in urine, point-of-care  
   testing for, 391, 393  
 Leukotrienes, in biowarfare, 610  
 Licensing, of laboratories, 244-246  
 Light microscopy, in diabetic nephropathy,  
 115-125  
 LightCycler, for polymerase chain reaction,  
 640  
 Lipid(s)  
   metabolism of, in liver, diabetes mellitus  
   and, 194-195

- profile of  
 in diabetes mellitus, 147-172  
 cardiovascular disease and, 159-162  
 causes of, 151  
 diagnostic decision-making in, 162-164  
 high-density lipoprotein, 156-158, 162-164  
 hyperglycemia treatment response, 165-166  
 hypertriglyceridemia, 149  
 interpretation of, 150  
 lipoprotein(a), 158-159  
 low-density lipoprotein, 155-156  
 management of, 164-168  
 postprandial, 154-155  
 remnant lipoproteins, 153-154  
 triglyceride-rich lipoproteins, 151-153, 163-164  
 typical, 147-149  
 in insulin resistance syndrome, 37-38  
 Lipoprotein(a), in diabetes mellitus, 158-159  
 Lipoprotein(s), in diabetes mellitus  
 high-density, 156-158, 160-164  
 intermediate-density, 151-153  
 low-density, 155-156, 159-162, 166-167  
 remnant, 153-154  
 very low-density, 151-154  
 Lipoprotein lipase, deficiency of, in insulin resistance syndrome, 38  
 Liposomes, as fluorescent carriers, in flow cytometry, 768  
 Lipotoxicity, insulin resistance in, 32-33, 36  
 Liver  
 biopsy of  
 in hypoglycemia, 94  
 in nonalcoholic steatohepatitis, 196  
 cirrhosis of, coagulation point-of-care testing in, 344  
 disease of, diabetes mellitus and, 193-207  
 cirrhosis, 199-201  
 glucose metabolism in, 193-194  
 hemochromatosis, 199  
 hepatitis C, 198-199  
 lipid metabolism in, 194-195  
 medication-induced, 197-198  
 steatohepatitis, 195-197  
 transplantation, 201-202  
 in glucose homeostasis, 82  
 transplantation of, point-of-care testing during, medical outcome impact of, 296  
 Luminox 100 (suspension array technology instrument), 718-719, 722  
 Lymphocytes. *See also* B lymphocytes; T lymphocytes.  
 flow cytometry studies of. *See also* Flow cytometry, in functional assays.  
 for CD marker detection, in lymphoproliferative disorders, 764-766, 769, 771-772  
 Lymphoma, flow cytometry in, 764-766, 769-772  
 cytokine imbalance in, 805-806  
 Lymphoproliferative disorders, flow cytometry in  
 leukemia, 764-766, 769, 771-772  
 low grade, 764-765  
 lymphoma, 764-766, 769-772, 805-806  
 Macrosomia, in gestational diabetes mellitus, 182-183, 185-186  
 Magnesium, abnormalities of, in uncontrolled diabetes mellitus, 106  
 Malaria, detection of, red cell flow cytometry in, 835-836  
 Market men's disease (tularemia), in biowarfare, 439, 447, 529-534, 646, 665  
 Masks, for biowarfare agent protection, 430-431  
 Maturity-onset diabetes of the young, 3-4, 34-35  
 Medical outcomes, point-of-care testing impact on, 285-303  
 concepts of, 286-288  
 definitions in, 286-288  
 in anticoagulation therapy monitoring, 293-294  
 in diabetes mellitus, 290-293  
 in drug monitoring, 293  
 in emergency room, 294-295  
 in intensive care unit, 295-296  
 in operating room, 296-297  
 in primary care, 297-299  
 in screening, 299  
 quality of evidence for, 289-290  
 Metabolic acidosis, diabetic. *See* Diabetes mellitus, uncontrolled.  
 Metabolism, oxidative, in lymphocyte activation, flow cytometry in, 784-785  
 Metformin, in glycated protein control, 70  
 Methylglyoxal  
 as glycation agent, 55-56  
 in diabetic complications, 58  
 measurement of, 70-71  
 Microalbuminuria, in diabetes mellitus, 113-114  
 assays for, 135-137  
 treatment of, 137-138  
 Microaneurysms, capillary loop, in diabetic nephropathy, 116, 120-121  
 Microbiology  
 flow cytometry in, 897-909  
 fluorescence measurements in, 900-902  
 for identification, 902-905



Microbiology (*Continued*)

- for susceptibility testing, 904-907
- for viruses, 907
- future of, 907
- inputs and outputs in, 897-898
- intrinsic parameters and, 900
- multiple aliquot problem in, 902-904
- multiplexing in, 903-904
- real-world considerations in, 902
- samples for, 899-900
- point-of-care tests in, 401-402
- Microparticles, in flow cytometry. *See* Suspension array technology.
- Microscopy
  - in diabetic nephropathy
    - electron, 125-127
    - light, 115-125
  - provider-performed, 375-387
    - coordination of, within hospital, 384-385
    - fecal leukocytes, 377-378
    - fern test, 378-379
    - personnel involved in, 377
    - pinworms, 380-382
    - regulations on, 376-377
    - seminal fluid, 378, 380
    - specimens for, 377
    - urine sediment, 382-384
- Micospheres, in molecular cytometry, 731-742
- Minimal model approach
  - in beta cell dysfunction, 44
  - in insulin resistance, 41
- Mitochondria
  - Bax gene transfer to, flow cytometry in, 870
  - defects of, in myelodysplastic syndrome, 815
  - gene mutations in, diabetes mellitus in, 35
- MODY (maturity-onset diabetes of the young), 3-4, 34-35
- Molecular beacons, for polymerase chain reaction, 639
- Molecular cytometry, microsphere-based, 731-742
  - applications of, 731-733
  - in nuclear receptor binding interaction analysis, 733-738
- Morbidity, as outcome measure, 286-288
- Mortality, as outcome measure, 286-288
- Multicolor flow cytometry. *See* Flow cytometry, eleven-color.
- Multidrug resistance gene products, flow cytometric detection of, on leukemic blasts, 766
- Multiplex analysis, in flow cytometry
  - in microbiology, 902-904
  - with suspension array technology, 722-723

- Multivariate gating analysis, in flow cytometry, 864-866
- Munitions, biologic warfare, 428-430
- Murray Valley encephalitis, in biowarfare, 496, 499
- Mycotoxins, in biowarfare, 600
- Myelodysplastic syndrome, 811-828
  - case history of, 816
  - definition of, 811
  - diagnosis of, 816-822
    - cytogenetic, 821-822
    - flow cytometry in, 818-821
    - morphologic, 816-818
  - epidemiology of, 812
  - pathogenic models of, 812-816
  - prognosis for, 822-823
  - progression of, to acute leukemia, 815-816
- Myocardial infarction, point-of-care testing in. *See* Cardiac markers, point-of-care testing for.
- Myoglobins, point-of-care testing for. *See* Cardiac markers, point-of-care testing for.
- National Diabetes Data Group criteria, for gestational diabetes mellitus, 177-181
- National Glycohemoglobin Standardization Program, 61-62
- Natural killer cells, CD8, flow cytometric detection of, 766
- Near patient testing. *See* Point-of-care testing.
- Neoantigens, expression of, flow cytometry in, 786-788
- Neonates, complications in, with gestational diabetes mellitus, 182-183, 186
- Nephropathy, diabetic, 111-145
  - clinical course of, 112-114
  - epidemiology of, 112-114
  - glycated proteins in, 58
  - monitoring of, 135-137
  - natural history of, 113-114
  - overt, 114
  - pathogenesis of, 127-133
  - pathology of, 114-127
  - risk factors for, 133-135
  - stages of, 137-140
  - treatment of, 137-140
- Neuroglycopenia
  - acute, 79-80, 93-94
  - chronic, 80
  - clinical features of, 80-81
  - subacute, 80
- Neurotransmitters, in biowarfare, 610-611
- Newcastle disease, in biowarfare, 579-585
- Niacin, in hypertriglyceridemia, in diabetes mellitus, 167-168

- Nipah virus encephalitis, in biowarfare, 477-478
- Nitrazine paper, for amniotic fluid pH determination, 378
- Nitric oxide detection, in Biowarfare Breathalyzer, 686
- Nitrite, in urine, point-of-care testing for, 391-393
- Nitroblue tetrazolium colorimetry, for fructosamine, 63-64
- Nitroprusside reaction, for ketone testing, 104
- Nonglucose stimuli, insulin response to, in beta cell function evaluation, 43-44
- Nonketotic hyperglycemia. *See* Diabetes mellitus, uncontrolled.
- Nuclear factor kappa B, translocation of, flow cytometry in, 786, 869-870
- Nuclear receptors, binding of, microsphere-based molecular cytometry studies of, 733-738
- Obesity  
   diabetes mellitus in, 3  
   weight reduction in, 164  
   insulin resistance in, 32-33  
   nonalcoholic steatohepatitis in, 195-197
- Occult blood, point-of-care testing for, 395-398
- Ohara's disease (tularemia), in biowarfare, 439, 447, 529-534, 646, 665
- Operating room, point-of-care testing in cost issues in, 276-277  
   medical outcome impact of, 296-297
- Oral glucose tolerance test  
   in gestational diabetes mellitus, 177-181  
   in insulin resistance, 41
- Oral hypoglycemic agents, liver disease due to, 197-198
- Osmolality, plasma, in uncontrolled diabetes mellitus, 102-103
- O'Sullivan and Mahan criteria, for gestational diabetes mellitus, 177-178
- Outcomes, medical. *See* Medical outcomes.
- Oxidative metabolism, in lymphocyte activation, flow cytometry in, 784-785
- Oxygen radicals  
   diabetic nephropathy and, 130  
   flow cytometry of, 784-785
- Pancreas  
   beta cells of. *See* Beta cells.  
   disorders of, diabetes mellitus in, 4
- Parasites, intracellular, detection of, red cell flow cytometry in, 835-836
- Parathyroidectomy, point-of-care testing during, 277, 296
- Patient satisfaction, as outcome measure, 286-288
- Peritoneal dialysis, in diabetic nephropathy, 139
- Peroxisome proliferator-activated receptors, binding of, microsphere-based molecular cytometry studies of, 735, 737
- pH  
   blood, in uncontrolled diabetes mellitus, 104-105  
   urine, point-of-care testing for, 391
- Pharyngitis, streptococcal, point-of-care testing for, 398-399
- Phosphate, abnormalities of, in uncontrolled diabetes mellitus, 106-107
- Phosphorylation, tyrosine, flow cytometry in, 780-782
- Piezophiles, in biowarfare, 623
- Pinworm examination, microscopic, 380-382
- Plague, in biowarfare, 439, 444-445, 523-529, 664  
   identification of, 647  
   pathology of, 528-529
- Plants, as biowarfare targets, 550, 552
- Plasma proteases, in biowarfare, 611-612
- Plasmodium, detection of, red cell flow cytometry in, 835-836
- Platelet(s)  
   dysfunction of, in insulin resistance syndrome, 38  
   function of, point-of-care testing of, 348
- Pneumonic plague, in biowarfare, 527-528
- Point-of-care testing  
   accuracy of, in acute testing, 326-328  
   acute. *See* Acute care testing.  
   alternatives to, 258  
   analytical performance of, 223-228  
   applications of, 222-223  
   attitudes toward, 331-333  
   benefits of, 270. *See also* Medical outcomes, point-of-care testing impact on.  
   billing for, 329-330  
   blood gases, 321-335  
   cardiac marker, 351-362  
   coagulation. *See* Coagulation testing, point-of-care.  
   communication for, 263  
   control sample analysis in, 262  
   costs of. *See* Cost issues, in point-of-care testing.  
   data management in, 264-266  
   glucose, 315-316  
   in acute testing, 328-330  
   definition of, 218-219, 375  
   devices for, 325-326  
   blood gases, 325-326

## Point-of-care testing (Continued)

- drug abuse, 367-369
  - glucose, 314-315
  - prothrombin time, 338-341
  - drug, 293, 363-374
  - electrolytes, 321-335
  - errors in, 224-227
  - example of, 234-236
  - future of, 236-238
  - gastric occult blood, 397-398
  - glucose. *See* Glucose, point-of-care testing for.
  - goals of, 270
  - group A streptococci, 398-399
  - Helicobacter pylori*, 298, 399-401
  - history of, 218-220
  - inspection program for, 243-244, 257
  - labor requirements for, cost issues in, 278-279
  - level of, decisions on, 256-257
  - management of, 228-232, 255-268
    - data management, 264-266, 315-316, 328-330
    - organization for, 255-260
    - quality assurance in. *See* Quality control and quality assurance, in point-of-care testing.
    - team approach to, 249-250, 255-260
  - medical outcomes and, 285-303
  - menu for, 221-222
  - microbiologic, 401-402
  - microscopy, 375-387
  - occult blood, 395-398
  - options for, in acute testing, 321-322
  - oversight of, 280
  - overview of, 217-239
  - perspectives on, 331-333
  - policies and procedures for, 230-231, 260-261
  - pregnancy, 402-403
  - principles of, 218-221
  - proficiency testing in, 262-263, 384-385
  - quality assurance in. *See* Quality control and quality assurance, in point-of-care testing.
  - regulatory issues in. *See* Regulatory issues, in point-of-care testing.
  - split sample testing in, 262-263
  - standardization in, 259
  - stool, 377-378, 395-398
  - team approach to, 249-250, 255-260
  - technology for, selection of, 258-259
  - tests available for, 221-222, 270
  - toxicology, 363-374
  - training for, 261-262
  - turnaround time in, 258
  - urine. *See* Urine testing, point-of-care.
  - utility of, 222-223
  - versus other testing options, 219-220
- Polymerase chain reaction, for biowarfare agent detection, 670-673
- amplification methods for, 635-636, 640-642
- Bacillus anthracis*, 643-644
  - brucellosis, 644
  - Burkholderia*, 644-645
  - Chlamydia psittaci*, 645
  - Coxiella burnetii*, 646
  - fluorescent probe technology for, 636-642
  - hantavirus, 650
  - hemorrhagic fever viruses, 649-650
  - hot start, 635
  - multiplex, 636
  - original methods, 634-635
  - product identification after, 635
  - real-time, 636, 640-642
  - reporter dyes for, 636
  - Staphylococcus aureus*, 646
  - variola virus (smallpox), 650
  - viruses, 648-650
  - Yersinia pestis*, 647
- Polyol pathway, diabetic nephropathy and, 130
- Potassium
- abnormalities of, in uncontrolled diabetes mellitus, 105
  - replacement of, in uncontrolled diabetes mellitus, 107
- Poultry
- avian influenza in, 562-571
  - Newcastle disease of, 579-585
- Pravastatin, in lipid disorders, in diabetes mellitus, 160-161
- Preeclampsia, diabetes mellitus and, 181-182
- Pregnancy
- cytokine imbalance in, 799
  - diabetes mellitus in. *See* Gestational diabetes mellitus.
  - fetomaternal hemorrhage detection in, red cell flow cytometry in, 830-831
  - glucose monitoring in, medical outcome impact of, 292-293
  - point-of-care tests for, 402-403
- Pregnancy-induced hypertension, diabetes mellitus and, 181-182
- Prenatal diagnosis, maternal blood samples for, 831
- Pressure-resistant organisms, in biowarfare, 623
- Primary care, point-of-care testing in, medical outcome impact of, 297-299
- Primus CLC Affinity method, for glycohemoglobins, 62
- Proficiency testing, for point-of-care testing, 262-263, 384-385
- Proinsulin, measurement of, in hypoglycemia, 91
- Proliferation, of lymphocytes, flow cytometry in, 788, 790-792, 851-853

- Proteases, in biowarfare, 611-612
- Protein(s), glycosylated. *See* Glycosylated proteins.
- Protein kinase C
- inhibitors of, in diabetic nephropathy, 140
  - prolonged activation of, diabetic nephropathy and, 129-130
- Protein tyrosine kinase, in phosphorylation, flow cytometry in, 780-782
- Protein tyrosine phosphatase, in phosphorylation, flow cytometry in, 780-782
- Proteinuria
- in diabetes mellitus
    - assays for, 135-136
    - onset of, 112
    - screening for, 136
    - treatment of, 137-139
  - point-of-care testing for, 391
- Prothrombin time, point-of-care testing for, 338-345
- description of, 338
  - devices for, 338-341
  - home, 339, 342-343
  - inpatient, 343-344
  - versus laboratory methods, 338-339
- ProTime device, 338, 341
- Pseudohypoxia, diabetic nephropathy and, 130
- Psychrophiles and psychrotrophs, in biowarfare, 623-624
- PT. *See* Prothrombin time.
- PTT (activated partial thromboplastin time), point-of-care testing for, 345-346
- Pyuria, point-of-care testing for, 383
- Q fever, in biowarfare, 439, 445-446, 534-540, 646
- pathology of, 538-540
- Quality control and quality assurance in flow cytometry, suspension array, 727-728
- in point-of-care testing, 260-264
    - acute, 330-333
    - glucose, 229-232
    - in large academic teaching hospital, 246-251
    - microscopy, 384-385
    - occult blood, 397-398
    - urine, 394-395
- Quantitative flow cytometry, 743-761
- activities promoting, 757-759
  - clinical applications of, 744-745
  - consensus conferences on, 757-759
  - guidelines for, quality assurance in, 745
  - in HIV infection, 846
  - observations on, 759
  - quality assurance in, 745
  - standards for, 744
  - surveys on
    - AIDS Clinical Trial Groups Quantitative Survey, 753-754
    - autofluorescence, 747-748
    - Centers for Disease Control, 751-752
    - College of American Pathologists Microbead Challenge Survey, 754-755
    - design of, 745-746
    - European Working Group Long-Term Quantitative Survey, 756-757
    - Fifth International Workshop on Leukocyte Differentiation Antigens, 752
    - fluorescence intensity quantitation, 751-757
    - instrument performance, 747-751
    - instrument setup, 748-750
    - International Society for Analytical Cytology Quantitative AIDS Survey, 752-754
    - Prestaining Antibody Binding Survey, 755-756
    - Quantification of CD38-PE Survey, 755
- Rabbit fever (tularemia), in biowarfare, 439, 447, 529-534, 646, 665
- Racial factors, in diabetic nephropathy, 135
- Radiation, organisms resistant to, in biowarfare, 624-626
- Radioimmunoassays, for glutamic acid decarboxylase antibodies, 21
- Rapidpoint Coag device, 341
- Reactive oxygen species, flow cytometry of, 784-785
- Receptors
- cell surface, aggregation of, flow cytometry in, 780
  - cytokine, in flow cytometry study design, 802-804
  - nuclear, binding of, microsphere-based molecular cytometry studies of, 733-738
- Red cell flow cytometry, 829-840
- clinical applications of, 829-830
  - direct agglutination test and, 834
  - in anemia, 835
  - in CD163 detection, 835
  - in cell survival evaluation, 834-835
  - in F-cell enumeration, 831-833
  - in fetal cell detection, 830-831
  - in fetomaternal hemorrhage, 830-831
  - in parasite infections, 835-836
  - in red cell mixture detection, 834
- Reference laboratories, for arboviral detection, 506

- Regulatory issues, in point-of-care testing, 218, 232-234, **241-253**  
 case study, in large academic teaching hospital, 246-251  
 guidelines, 242-244  
 laboratory inspection, 244-246, 257  
 licensing, 244-246  
 provider-performed microscopy, 376-377  
 Remnant lipoproteins, in diabetes mellitus, 153-154  
 Reticulocytes, detection of, flow cytometry in, 834  
 Retinopathy, diabetic, glycosylated proteins in, 58  
 Rh antigen mismatch, fetomaternal hemorrhage and, 830-831  
 Rheumatoid arthritis, cytokine imbalance in, 799  
 Ribavirin, for viral infections, 488  
 Ricin toxin, in biowarfare, 441, 459-460, 599-600, 665, 672  
 Rift Valley hemorrhagic fever, in biowarfare, 440, 452-455, 476, 478-479, 481, 497, 502  
 RNA, HIV, measurement of, flow cytometry in, 842-843  
 Roche Diagnostics CardiacT test, 354-355  
 Roche Unimate assay, for glycohemoglobins, 61-62  
 Ruggedized Advanced Pathogen Identification Device, 640, 642
- Sacks and Sacks criteria, for gestational diabetes mellitus, 178  
 Safety, for biowarfare agent handling, 417-418, 428  
 foot-and-mouth disease virus, 561  
 in laboratory studies, 508, 631-632, 662-663  
 St. Louis encephalitis, in biowarfare, 496, 499  
 Screening tests, point-of-care  
 for illicit drugs. *See* Drugs, point-of-care testing for, in drug abuse.  
 medical outcome impact of, 299  
 Seminal fluid, microscopic examination of, 378, 380  
 Semliki Forest virus infections, 500  
 Septicemic plague, in biowarfare, 526-527  
 Sézary's syndrome, flow cytometry in, cytokine imbalance in, 805-806  
 Sheep, foot-and-mouth disease of, 553-562  
 Sickle cell disease, red cell flow cytometry in, 833-834  
 Sigma Diagnostics Alpha Dx test, for cardiac markers, 356  
 Signal amplification, for polymerase chain reaction, 642
- Single nucleotide polymorphisms, genotyping of, microspheres in, 732  
 Smallpox, in biowarfare  
 clinical features of, 439, 448-449, 479, 481  
 detection methods for, 650, 665  
 diagnosis of, 481  
 history of, 423  
 immune response to, 484-485  
 outbreaks of, 476-477  
 pathology of, 481-482  
 targets of, 481, 483-484  
 treatment of, 439, 449-450, 488  
 SmartCycler system, for polymerase chain reaction, 642  
 Smoking, diabetic nephropathy and, 135  
 Sodium, abnormalities of, in uncontrolled diabetes mellitus, 105  
 Somatostatinoma, diabetes mellitus in, 4  
 Sorbitol, accumulation of, diabetic nephropathy and, 130  
 Specific gravity, of urine, point-of-care testing for, 391  
 Specimen collection and handling, for biowarfare agents, 503, 506-508, 632-634, 663, 667  
 Spectral address, in suspension array technology, 715-719  
 Spectral Diagnostics Cardiac STATus test, 355  
 Sperm, microscopic detection of, 378, 380  
 Staphylococcal enterotoxins, in biowarfare, 441, 457-459, 598-599, 646, 665  
 STAT process, versus point-of-care testing, 333-334  
 Statins, in hyperlipidemia, in diabetes mellitus, 166  
 Steatohepatitis, nonalcoholic, in diabetes mellitus, 195-197  
 Steatosis, in diabetes mellitus, 194-195  
 Stiff-man syndrome, diabetes mellitus in, 5, 21  
 Stool  
 bacterial identification in, flow cytometry in, 899  
 point-of-care testing of leukocytes, 377-378  
 occult blood, 395-398  
 Stratus CS test, for cardiac markers, 356  
 Streptococci, group A, point-of-care testing for, 398-399  
 Sulfonyleureas  
 liver disease due to, 197-198  
 measurement of, in hypoglycemia, 91  
 Surveillance, for arboviruses, 508-509  
 Susceptibility testing, of microorganisms, flow cytometry in, 904-907  
 Suspension array technology, **713-729**  
 beyond dual-color, 719  
 clinical applications of, 723-724

- cost-effectiveness of, 726
- dual-color, 717-719
- fluorospheres in, 714, 720
- in conventional flow cytometer, 716-717
- in dedicated flow cytometer, 718-719
- in HIV infection, 849-850
- in hybrid flow cytometer, 717-718
- innovations in, 715-716
- limitations of, 720
- morphospectral characteristics of, 715-716
- multiplexing in, 722-723
- pitfalls in, 723
- principles of, 713-715
- quality control in, 727-728
- quantitative, 725-726
- research applications of, 723-724
- sample handling and processing for, 724-725
- semiquantitative, 725-726
- single-color, 716-717
- specificity and sensitivity issues in, 720-722
- spectral address in, 715-719
- three-dimensional, 719
- Swine
  - foot-and-mouth disease of, 553-562
  - swine fever in, 571-578
- SYBR Green I, for polymerase chain reaction, 637
- Syndrome X, 37-38
- T-2 mycotoxin, in biowarfare, 600
- T lymphocytes
  - flow cytometry studies of, 773-774. *See also* Flow cytometry, in functional assays; *specific CD molecules.*
  - eleven-color
    - antigen-specific, in cancer, 708-709
    - in atopy, 706-708
    - interferon-g-polarized, in leprosy, 706-708
    - interleukin-4-polarized, in leprosy, 706-708
    - naive, 700-706
    - helper, cytokine production in, 796-797
    - in beta cell destruction, 23-25
  - TaqMan hydrolysis probes, for polymerase chain reaction, 637
  - TAS devices, 338
  - Terrorism, with biological agents. *See* Biowarfare.
  - Tetramer assay, for T lymphocytes, in HIV infection, 846-847, 850
  - Thermophiles, in biowarfare, 623
  - Thiazolidinediones, liver disease due to, 198
  - Tick-borne encephalitis, in biowarfare, 480, 497, 499, 501
  - Tina-Quant glycosylated hemoglobin method, 62
  - Tissue-based biosensors, for biowarfare agents, 686-687
  - Tosoh method, for glycohemoglobins, 62
  - Toxicology, point-of-care testing in, 363-374
    - advantages of, 372
    - alcohol, 369-370
    - confirmation of, 365
    - devices for, 367-369
    - disadvantages of, 372-373
    - for medical care guidance, 365-367
    - specimens for, 366
    - types of, 364-365
    - versus central laboratory methods, 370-371
  - Toxins, in biowarfare, 593-605
    - aerosolization of, 594
    - botulinum, 441, 455-457, 596-598, 645-646, 665
    - chemical versus biological, 595, 601-604
    - classification of, 595-596
    - concepts of, 593-595
    - definitions of, 593-595
    - dosage of, 594-595
    - exposure conditions for, 594
    - lethality of, 594, 596-597
    - ricin, 441, 459-460, 599-600, 665, 672
    - staphylococcal enterotoxin, 441, 457-459, 598-599, 646, 665
    - T-2 mycotoxin, 600
    - types of, 593-594
  - Transcription factors, activation of, flow cytometry in, 785-786
  - Transforming growth factor-b
    - in diabetic nephropathy pathogenesis, 131
    - inhibitors of, in diabetic nephropathy, 140
  - Transfusions
    - multiple, phenotyping after, flow cytometry in, 834
    - point-of-care testing during, 296-297
  - Transplantation
    - bone marrow, in hyper IgM syndrome, flow cytometry after, 788-789
    - kidney, in diabetic nephropathy, 139-140
    - liver
      - diabetes mellitus and, 201-202
      - point-of-care testing during, medical outcome impact of, 296
  - Triage, point-of-care testing in, medical outcome impact of, 295
  - Triglycerides, excess of. *See* Hypertriglyceridemia.
  - Troglitazone, liver disease due to, 198
  - Troponins, point-of-care testing for. *See* Cardiac markers, point-of-care testing for.

- Trypanosomiasis, detection of, red cell flow cytometry in, 835-836
- Tularemia, in biowarfare, 439, 447, 529-534, 646, 665  
 pathology of, 533-534
- Tumor necrosis factor- $\alpha$   
 excess of, insulin resistance in, 33  
 in beta cell destruction, 16  
 in biowarfare, 609-610
- TUNEL method, for DNA analysis, in myelodysplastic syndrome, 814
- Typhoidal tularemia, 532-533
- Tyramide, in amplification staining, in flow cytometry, 769
- Tyrosine phosphorylation, flow cytometry in, 780-782
- Ulceroglandular tularemia, 531-532
- United States Army Medical Research Institute of Infectious Diseases, 680-681, 683-685
- Urea breath test, for *Helicobacter pylori*, 401
- Urease test, for *Helicobacter pylori*, 400-401
- Uremia, carbamylated hemoglobin formation in, 61
- Urinary tract infections, point-of-care testing for, 297-298, 392-393
- Urine testing  
 microbiologic, flow cytometry in, 899  
 point-of-care, 389-395  
 errors in, 390  
 for amniotic fluid, 378-379  
 for illicit drugs. *See* Drugs, point-of-care testing for, in drug abuse.  
 for infections, 297-298, 392-393  
 for pregnancy, 402-403  
 inpatient, 393-395  
 microscopic sediment examination in, 382-384  
 multiple test pads for, 390  
 outpatient, 392-393
- Urobilinogenuria, point-of-care testing for, 391
- Ursodeoxycholic acid, in nonalcoholic steatohepatitis, 197
- Vaccines, for biowarfare agent protection, 431-432, 681-684  
 botulinum toxin, 598  
 viral, 484-485
- Variola virus. *See* Smallpox.
- Vasculopathy, diabetic, glycated proteins in, 58, 65-66
- Vasectomy, sperm detection after, microscopic, 378, 380
- Venezuelan equine encephalitis, in biowarfare, 440, 450-452, 496
- animal models for, 485-486  
 clinical features of, 477-478, 480  
 detection methods for, 648, 665, 669  
 diagnosis of, 480  
 immune response to, 484  
 outbreaks of, 476  
 pathology of, 480  
 targets of, 480, 483  
 taxonomy of, 499
- Viral infections  
 diabetes mellitus in, 5  
 flow cytometry in, 907  
 in biowarfare, 475-493. *See also* Smallpox.  
 animal models for, 485-486  
 arthropod-transmitted, 495-512. *See also specific pathogens and diseases.*  
 clinical features of, 477-481  
 detection methods for, 647-650  
 diagnosis of, 480-481, 486-487  
 encephalitis. *See* Encephalitis, viral.  
 hemorrhagic fevers. *See* Hemorrhagic fever(s), viral.  
 immune response to, 484-485  
 outbreaks of, 476-477  
 pathology of, 479-482  
 plant-directed, 550  
 targets of, 480-484  
 treatment of, 487-488
- Visual microscopic counting (KB) method, for fetomaternal hemorrhage detection, 830-831
- Water trapper's disease (tularemia), in biowarfare, 439, 447, 529-534, 646, 665
- Weapons of mass destruction. *See* Biowarfare.
- West Nile encephalitis, in biowarfare, 496, 499, 502  
 clinical features of, 478, 480  
 detection methods for, 648-649  
 diagnosis of, 480, 487  
 immune response to, 484  
 outbreaks of, 476  
 pathology of, 480  
 targets of, 480
- Western blot test, for arboviral antigens, 506
- Western equine encephalitis, in biowarfare, 440, 450-452, 480, 496  
 detection methods for, 648  
 taxonomy of, 499-500
- Whipple's triad, hypoglycemia in, 93
- X-linked disorders, hyper IgM syndrome, flow cytometry in, 787-789
- Yellow fever, in biowarfare, 440, 452-455, 478-480, 496, 499
- Yersinia pestis* infections. *See* Plague.



